246 related articles for article (PubMed ID: 24988963)
21. Interferons and natalizumab for multiple sclerosis.
Clar C; Velasco Garrido M; Gericke C; Busse R
GMS Health Technol Assess; 2008 Oct; 4():Doc09. PubMed ID: 21289915
[TBL] [Abstract][Full Text] [Related]
22. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
23. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
[TBL] [Abstract][Full Text] [Related]
24. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
Lage MJ; Carroll CA; Fairman KA
J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
[TBL] [Abstract][Full Text] [Related]
25. [Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain].
Rubio-Terrés C; Arístegui Ruiz I; Medina Redondo F; Izquierdo Ayuso G
Farm Hosp; 2003; 27(3):159-65. PubMed ID: 12835817
[TBL] [Abstract][Full Text] [Related]
26. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
27. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
[TBL] [Abstract][Full Text] [Related]
29. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
Nuijten M; Mittendorf T
Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
[TBL] [Abstract][Full Text] [Related]
30. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Darbà J; Kaskens L; Sánchez-de la Rosa R
J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
[TBL] [Abstract][Full Text] [Related]
32. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive cost-effectiveness analysis of treatments for multiple sclerosis.
Newton AN; Stica CM
Int J MS Care; 2011; 13(3):128-35. PubMed ID: 24453716
[TBL] [Abstract][Full Text] [Related]
34. [Current treatment of multiple sclerosis].
Gout O; Bensa C; Assouad R
Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
[TBL] [Abstract][Full Text] [Related]
35. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
Baker DP; Pepinsky RB; Brickelmaier M; Gronke RS; Hu X; Olivier K; Lerner M; Miller L; Crossman M; Nestorov I; Subramanyam M; Hitchman S; Glick G; Richman S; Liu S; Zhu Y; Panzara MA; Davar G
J Interferon Cytokine Res; 2010 Oct; 30(10):777-85. PubMed ID: 20836711
[TBL] [Abstract][Full Text] [Related]
36. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy).
Moccia M; Loperto I; Lanzillo R; Capacchione A; Carotenuto A; Triassi M; Brescia Morra V; Palladino R
BMC Health Serv Res; 2020 Aug; 20(1):797. PubMed ID: 32847587
[TBL] [Abstract][Full Text] [Related]
37. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
38. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
[TBL] [Abstract][Full Text] [Related]
39. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
Heisen M; Treur MJ; van der Hel WS; Frequin ST; Groot MT; Verheggen BG
J Med Econ; 2012; 15(6):1149-58. PubMed ID: 22737996
[TBL] [Abstract][Full Text] [Related]
40. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]